Werewolf Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HOWL research report →
Range $1 – $1
Price Chart
About the company
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity.
- CEO
- Daniel J. Hicklin
- IPO
- 2021
- Employees
- 39
- HQ
- Watertown, MA, US
Get TickerSpark's AI analysis on HOWL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $46.00M
- P/E
- -1.83
- PEG
- -0.02
- P/S
- 2.43
- P/B
- 7.55
- EV/EBITDA
- -0.60
- Div Yield
- 0.00%
- Gross Margin
- 80.41%
- Op Margin
- -90.91%
- Net Margin
- -133.90%
- ROE
- -187.29%
- ROIC
- -282.47%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-1,634,000-2401.4%
- Op Income
- $-60,677,000
- Net Income
- $-60,822,000+13.7%
- EPS
- $-1.32+19.0%
- OCF Growth
- -7.3%
- FCF Growth
- -6.8%
- 52W High
- $1.20
- 52W Low
- $0.27
- 50D MA
- $0.99
- 200D MA
- $0.71
- Beta
- 0.29
- RSI (14)
- 43
- Avg Volume
- 5.71M
No earnings-call transcripts are available for HOWL yet.
- Free Float
- 82.2%
- Shares Outstanding
- 48.60M
- Float Shares
- 39.93M
of shares held by institutions
47 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 2.39M | ▼ 4.29M |
| Balyasny Asset Management L.P. | 1.79M | ▲ 1.79M |
| Vanguard Group Inc | 1.41M | 0 |
| Vanguard Capital Management LLC | 1.22M | 0 |
| Lynx1 Capital Management LP | 657.79K | 0 |
| Sphera Funds Management Ltd. | 626.81K | 0 |
| Dc Funds, LP | 589.10K | 0 |
| Jane Street Group, LLC | 564.53K | ▲ 312.69K |
| Renaissance Technologies LLC | 550.93K | ▼ 123.70K |
| Hrt Financial LP | 415.19K | ▲ 415.19K |
| Geode Capital Management, LLC | 407.14K | ▲ 71.33K |
| Verdad Advisers, LP | 348.71K | ▲ 318.95K |
Held by 20 ETFs
Biggest fund positions in HOWL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 6, 26 | EVNIN LUKE | sell | 35,770 |
| Jul 7, 26 | EVNIN LUKE | sell | 107,429 |
| Jun 29, 26 | EVNIN LUKE | sell | 157,084 |
| Jun 17, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 389,216 |
| Jun 17, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 27,695 |
| Jun 12, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 159,119 |
| Jun 15, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 120,216 |
| Jun 16, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 139,686 |
| Jun 12, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 11,322 |
| Jun 15, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 8,554 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HOWL coverage
Recent articles, reports, and earnings notes.
No research on HOWL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HOWL report →Werewolf Therapeutics' Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting
globenewswire.com · Nov 9
Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting
globenewswire.com · Oct 30
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why
zacks.com · Oct 13
New Strong Buy Stocks for October 9th
zacks.com · Oct 9
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Has Average Target Price of $4.00 According to Analysts
defenseworld.net · Sep 30
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
globenewswire.com · Sep 24
Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders?
gurufocus.com · Sep 9
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
globenewswire.com · Sep 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.